PRAX News and Press, Praxis Precision Medicines Inc. From 07/28/23

2023-07-28 13:22:08 ET Larimar Therapeutics ( NASDAQ: LRMR ), which has a candidate in phase 2 for Friedreich's Ataxia ("FA"), is up 22% in Friday afternoon trading, a beneficiary of Biogen's ( BIIB ) announcement to acquire Reata Pharmaceuticals ( RETA ) for more th...

2023-07-24 19:01:51 ET Summary In the last one year, Praxis stock has been decimated because of many trial failures. The company is still planning phase 3 trials of their lead asset. They have very little cash. Sometimes, preclinical stage companies have multibillion...

Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3 million Cash runway extended into Q1 2025 Phase 2 Photoparoxsymal Response (PPR) study to evaluate PRAX-628 expected to read-out by YE 2023 Plan to begin ulixacaltamide...

2023-06-16 05:59:42 ET Praxis Precision Medicines ( NASDAQ: PRAX ) shares fell 6.15% premarket on Friday after the biopharma company priced its securities offering to raise around $59.1M in gross proceeds. The offering comprises 55.15M ordinary share...

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imba...

2023-06-15 16:25:12 ET Praxis Precision Medicines ( NASDAQ: PRAX ) said Thursday it plans to conduct a public offering of its common stock. All shares in the offering will be offered by the company. The underwriters are expected to have a 30-day option to purchase up to an...

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imba...

2023-06-09 13:01:49 ET Praxis Precision Medicines ( NASDAQ: PRAX ) added ~4% on Friday after announcing results from an end-of-Phase 2 meeting with the FDA regarding plans to advance its lead candidate ulixacaltamide for Phase 3 development in movement disorder, Essential Tremor...

Phase 3 program to include one parallel group study and one randomized withdrawal study mADL11 as primary endpoint Single 60 mg/day dose to be tested BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmac...

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imba...